厄贝沙坦与依拉普利单独或联合给药治疗402例糖尿病肾病临床观察

The Clinical Observation of Aprovel and Enalapril Alone or Together for 402 Cases of Diabetic Kidney Disease

目的:探讨厄贝沙坦与依拉普利联合给药治疗糖尿病肾病的临床效果。方法:将402例糖尿病肾病患者随机分为观察组、对照组1和对照组2三组,各134例,观察组联合给药治疗,对照组1和2分别单独给药治疗。结果:三组患者治疗后的24h尿蛋白定量均较治疗前有明显下降(P<0.05),其中观察组下降程度显著多于两对照组(P<0.01);治疗后三组患者所有次指标与治疗前比较差异均无统计学意义(P>0.05)。结论:与单独给药比较,厄贝沙坦与依拉普利联用治疗糖尿病肾病不仅降尿蛋白作用更显著,而且能更好地保护肾脏功能,值得临床推广应用。

Objective： To explore the effect of aprovel and enalapril in treatment of diabetic nephropathy.Methods： 402 cases of diabetic nephropathy patients were randomly divided into observation group, control group land control group 2, all 134 cases, the observation group combination drug therapy, control group 1 and 2 separately to drug treatment.Results： The 24 h urine protein quantitative in three groups of patients after treatment than before treatment decreases evidently （P〈0.05）, the observation group of 24 h urine protein significant decline than control greup（P〈0.01）.After treatment, the three groups were all times index and compared before treatment were no statistical significance （P〉0.05）.Conclusion： Aprovel and enalapril compare with single dose in treatment of diabetic nephropathy not only drop urine protein more significant role, but also can better protect renal function, it is worth clinical application.